Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JayjayUSA12007on Mar 25, 2019 12:58am

149 Views

Post# 29529948

RE:Tesamorelin against NAFLD clinical trial started in Jan 2019

Thanks for other member(s) feedback to facts (incorrect) that I cited.

Correction for Item# 1:
"1/ This trial focus on NAFLD and early NASH patients in non-HIV population, which recruting criteria excludes late state NASH patients having "known cirrhosis, or Child-Pugh score ≥7, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam". These are late state NASH symptoms with Child–Pugh score class B and later.

Bullboard Posts

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles